A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Phase 1 Completed 28 enrolled Global Alliance for TB Drug Development

NaSingle-groupOpen-labelTreatment

Summary

A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects

Timeline

Start: 2022-06-30
Primary completion: 2022-09-26
Completion: 2022-09-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Digoxin	Other / unclassified	0.25 mg	Oral
Subject	Midazolam	Small molecule	2 mg	Oral
Subject	TBAJ-876	Small molecule	200 mg	Oral

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Summary

Timeline

Drugs

Indications